U-46619
Based on 16 publication(s) in Google Scholar
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.61%
- CAS No.: 56985-40-1
- Formule: C21H34O4
- Masse moléculaire:350.49
-
Stockage:
Solution, -20°C, 2 years
Publications Citing Use of MedChemExpress (MCE) U-46619
More- Int J Biol Macromol. 2025 May 7:144068. [Abstract]
- Free Radic Biol Med. 2024 Nov 20:225:333-345. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116505. [Abstract]
- J Agric Food Chem. 2022 Jan 26;70(3):785-793. [Abstract]
- Int J Mol Med. 2025 Dec;56(6):228. [Abstract]
- Neurobiol Dis. 2026 Jun 1:223:107390. [Abstract]
- Biochem Pharmacol. 2025 Oct:240:117107. [Abstract]
- J Ethnopharmacol. 2025 Mar 26:344:119564. [Abstract]
- Eur J Pharmacol. 2025 Jun 3:177807. [Abstract]
- Mol Neurobiol. 2025 Jan;62(1):366-385. [Abstract]
- Stem Cell Rev Rep. 2026 Jan 30;22(3):1325-1340.
- Biochim Biophys Acta Mol Basis Dis. 2024 Jul 25:167437. [Abstract]
- Mol Nutr Food Res. 2022 Jul;66(13):e2200166. [Abstract]
- J Appl Physiol (1985). 2026 Jan 30. [Abstract]
- Int J Chron Obstruct Pulmon Dis. 2024 Jul 8:19:1591-1601. [Abstract]
- J Cancer Res Clin Oncol. 2024 Sep 19;150(9):424. [Abstract]
-
WB
-
WB
-
Others
-
Others
-
WB
Activité biologique
|
TXA2/TP |
U-46619 (1 nM-10 μM) causes platelets shape change and aggregation in a concentration-dependent manner, and with EC50s of 0.58 μM and 0.013 μM for aggregation and shape change, respectively[1].
U-46619 (10 nM-10 μM) increases internal Ca2+ concentration ([Ca2+]i) and activates phosphoinositide (PI) hydrolysis in a concentration-dependent manner with a similar concentration-dependency[1].
U-46619 (3 nM-10 μM) also activates GTPase concentration-dependently in the membranes derived from platelets[1].
U-46619 improves the differentiation efficiency of human induced pluripotent stem cells into endothelial cells by activating both p38MAPK and ERK1/2 signaling pathways[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:12-15 weeks-old male and female SHR[2]
-
Dosage:5 μg/kg
-
Administration:Intravenous injection
-
Result:Induceed a significant increase of MABP after 1 min in male SHR.
Chemical Information
-
CAS No. 56985-40-1
-
Appearance Liquid
-
Masse moléculaire 350.49
-
Formule C21H34O4
-
Color Colorless to light yellow
-
SMILES
O=C(O)CCC/C=C\C[C@H]1[C@@]2([H])CO[C@@](C2)([H])[C@@H]1/C=C/[C@@H](O)CCCCC
-
Synonyms
9,11-Methanoepoxy PGH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Solution, -20°C, 2 years
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
FKBP5 inhibitor suppresses platelet activation and thrombosis by inhibiting IKBKE/PI3K/Rap1 pathway. [Abstract]2025 May 7:144068. PMID: 40345291 -
Free Radic Biol Med
Inhibition of acid-sensing receptor GPR4 attenuates neuronal ferroptosis via RhoA/YAP signaling in a rat model of subarachnoid hemorrhage. [Abstract]2024 Nov 20:225:333-345. PMID: 39393553
U-46619 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2024 Nov 20:225:333-345. [Abstract]
U-46619 (0.1 μg/kg). Representative protein blot band.
-
Cell Rep
Tunneling nanotube-mediated stem cell immunomodulation dysfunction promotes adipose inflammation and insulin resistance in GDM. [Abstract]2025 Nov 25;44(11):116505. PMID: 41187060
U-46619 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Nov 25;44(11):116505. [Abstract]
Adding the RhoA activator U46619 (0.1 μM; 24 h) can partially restore the effect of Wnt5a knockdown on downstream RhoA and Rock1 phosphorylation.
-
J Agric Food Chem
Novel Peptide Motifs Containing Asp-Glu-Gly Target P2Y12 and Thromboxane A2 Receptors to Inhibit Platelet Aggregation and Thrombus Formation. [Abstract]2022 Jan 26;70(3):785-793. PMID: 35016500 -
Int J Mol Med
2025 Dec;56(6):228. PMID: 41133478
U-46619 purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2025 Dec;56(6):228. [Abstract]
The expression of autophagy-related proteins in colorectal cancer cells after the addition of the MAPK/ERK pathway activator U-46619 (2 μM) was detected by Western blotting.
-
Neurobiol Dis
Aquaporin 4 knockdown alleviates traumatic brain edema and reduces neuronal axonal growth cone collapse via the RhoA/ROCK pathway. [Abstract]2026 Jun 1:223:107390. PMID: 41967652 -
Biochem Pharmacol
2025 Oct:240:117107. PMID: 40619010
U-46619 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Oct:240:117107. [Abstract]
The summary shows concentration-dependent post-relaxation contraction induced by U46619 (1–1000 nmol/L) in TRPV4fl/fl and TRPV4SMCki/ki mouse aorta.
-
J Ethnopharmacol
2025 Mar 26:344:119564. PMID: 40015536
U-46619 purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2025 Mar 26:344:119564. [Abstract]
Washed human platelets were pretreated with different doses of IsA or solvent in the presence of 1 mM CaCl₂, followed by stimulation with thrombin (0.04 U/mL), collagen (1 μg/mL), and U46619 (0.3 μM). ADP (2 μM)-induced aggregation was performed using platelet-rich plasma.
-
Eur J Pharmacol
Morin ameliorates coronary artery relaxation by activating TRPV4-eNOS-NO signalling in high-salt diet-fed rats. [Abstract]2025 Jun 3:177807. PMID: 40472987 -
Mol Neurobiol
Gastrodin Ameliorates Post-Stroke Depressive-Like Behaviors Through Cannabinoid-1 Receptor-Dependent PKA/RhoA Signaling Pathway. [Abstract]2025 Jan;62(1):366-385. PMID: 38856794 -
-
Biochim Biophys Acta Mol Basis Dis
Methylglyoxal induces endothelial cell apoptosis and coronary microvascular dysfunction through regulating AR-cPLA2 signaling. [Abstract]2024 Jul 25:167437. PMID: 39067539 -
Mol Nutr Food Res
A Collagen-Derived Oligopeptide from Salmo salar Collagen Hydrolysates Restrains Atherogenesis in ApoE-/- Mice via Targeting P2 Y12 Receptor. [Abstract]2022 Jul;66(13):e2200166. PMID: 35490399 -
J Appl Physiol (1985)
Attenuated cyclooxygenase-mediated vasodilation in cutaneous microvasculature with no difference in platelet aggregation in women with endometriosis. [Abstract]2026 Jan 30. PMID: 41615377 -
Int J Chron Obstruct Pulmon Dis
Exercise Attenuate Diaphragm Atrophy in COPD Mice via Inhibiting the RhoA/ROCK Signaling. [Abstract]2024 Jul 8:19:1591-1601. PMID: 39005647 -
J Cancer Res Clin Oncol
MYO3B promotes cancer progression in endometrial cancer by mediating the calcium ion-RhoA/ROCK1 signaling pathway. [Abstract]2024 Sep 19;150(9):424. PMID: 39297944
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (605 KB)
- English - EN (605 KB)
- Français - FR (605 KB)
- Deutsch - DE (605 KB)
- Norwegian - NO (605 KB)
- Español - ES (605 KB)
- Swedish - SV (605 KB)
- Italian - IT (605 KB)
- Korean - KR (605 KB)
- Portuguese - PT (605 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ohkubo S, et al. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets. Br J Pharmacol. 1996 Mar;117(6):1095-104. [Content Brief]
[2]. Su L, et al. The prostaglandin H2 analog U-46619 improves the differentiation efficiency of human induced pluripotent stem cells into endothelial cells by activating both p38MAPK and ERK1/2 signaling pathways. Stem Cell Res Ther. 2018 Nov 15;9(1):313. [Content Brief]
[3]. Schirner M, et al. U 46619 induces different blood pressure effects in male and female spontaneously hypertensive rats (SHR). Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):469-73. [Content Brief]
[4]. Chen S, et al. Roles of the RhoA-ROCK Signaling Pathway in the Endothelial H2S Production and Vasodilation in Rat Cerebral Arteries. ACS Omega. 2022 May 20;7(22):18498-18508. [Content Brief]
[5]. Nie D, et al. Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho. Cancer Res. 2008 Jan 1;68(1):115-21. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)